1. Targeting E3 Ubiquitin Ligases and Deubiquitinases in Ciliopathy and Cancer
   Takashi Shiromizu et al, 2020, IJMS CrossRef
2. Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
   Donglu Wu et al, 2020, Front. Oncol. CrossRef
3. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity
   Xin-Hui Zhang et al, 2021, J. Med. Chem. CrossRef
4. Primary Cilia–Related Pathways Moderate the Development and Therapy Resistance of Glioblastoma
   Minghao Li et al, 2021, Front. Oncol. CrossRef
5. A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
   Hao Wang et al, 2021, Front. Oncol. CrossRef
6. Aurora A and AKT Kinase Signaling Associated with Primary Cilia
   Yuhei Nishimura et al, 2021, Cells CrossRef
7. Treatment of Toxoplasmosis: An Insight on Epigenetic Drugs
   Paolo Guglielmi et al, 2022 CrossRef
8. The application of histone deacetylases inhibitors in glioblastoma.
   Rui Chen et al, 2020, J Exp Clin Cancer Res CrossRef
9. Promising Chemotherapy for Malignant Pediatric Brain Tumor in Recent Biological Insights
   Qian Zhou et al, 2022, Molecules CrossRef
10. Glioblastoma: Current Status, Emerging Targets, and Recent Advances
    Amandeep Thakur et al, 2022, J. Med. Chem. CrossRef
11. Effects of tubastatin A on adrenocorticotropic hormone synthesis and proliferation of AtT-20 corticotroph tumor cells
    Rie Hagiwara et al, 2022, Endocr J CrossRef
12. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer
    Yuchen Bai et al, 2022, Front. Immunol. CrossRef